Novel Use of Ketotifen (Mast Cell Stabilizer) in Fibromyalgia: A Pilot Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Indianapolis |
| State: |
|
Indiana |
| Zip Code: |
|
46202 |
| Conditions: |
|
Fibromyalgia |
| Purpose: |
|
The purpose of this 10-week study is to determine the effects of a medication called
Ketotifen on inflammation (blood) markers; pain sensitivity; and fibromyalgia-related pain.
Ketotifen works by inhibiting (to prevent or slow down) certain substances in the body that
are known to cause inflammation. It is an antihistamine that reduces the harmful effects of
histamine. The ophthalmic (eye drops) formulation of ketotifen has been approved by the
Food and Drug Administration (FDA) and has been available in the United States for more than
a decade. Oral (taken by mouth) ketotifen has been in available in other countries for
several decades. Commonly prescribed for the maintenance treatment of asthma and allergic
rhinitis, ketotifen has long track record of safety. To date, the oral form of ketotifen has
not been approved by the FDA, therefore this study is referred to as an "investigational
drug study." Prior to opening recruitment an "investigational new drug" (IND) application
which included scientific data and information regarding human safety plans was submitted to
and approved by the FDA.
|
| Study Summary: |
|
Approximately 46 subjects will be participating in this research. Each subject will be
randomized (like flipping a coin) to one of two groups; approximately 23 volunteers will
be randomized to receive the active medication and 23 will receive the placebo. Both groups
will be "blinded" (will not know) to which group they have been assigned.
The study will be conducted at the Indiana University Clinical Research Center for Pain
(CRCP), located on the IUPUI campus in the National Institute of Fitness and Sport
building,at 250 University Blvd.,Suite 118 Indianapolis, Indiana, 46202.
To summarize: The subject will be asked to visit the CRCP on four separate occasions:
Initial Screening, Week 1, Week 2, and Week 10. This study also includes, answering
questionnaires, a blood samples drawn on two separate occasions, taking study medication,
maintaining a written medication diary and agreeing to remain in weekly contact with the
study team to answer a short side effect questionnaire. The side effect questionnaire will
be conducted from week 1-4 and then once every 2 weeks from week 4-10.
Study Overview:
Week 0 (clinic visit 1):
1. Informed consent and initial screening questionnaire,
2. Review of all current medications
3. Light physical assessment, e.g. blood pressure, height, weight
4. The investigators will obtain a urine sample for a urine pregnancy test (UPT) and
screening blood samples (approximately 17.5 ml /3.3 teaspoonfuls) from a vein in the
subject's arm
5. Complete short thumb pressure testing in order to set the testing parameters for
futures tests (week 1 and week 10)
6. Receive 'pain score' wrist monitor with instructions to record his/her pain level
three times each day for one week
7. Receive a one-week medication packet along with instructions to take one tablet twice a
day for seven days along with entering dosing information in a medication diary.
Week 1 (clinic visit 2):
1. Submit his/her pain score wrist monitor
2. Submit his/her medication diary for review and return any unused medication
3. Complete the self-assessment questionnaires via computer
4. Undergo a thumb pressures pain sensitivity test
5. If qualified to continue, the subject will receive the next 7-day supply of either a
placebo or the active medication, ketotifen 1 mg. along with verbal and written
instructions and a medication diary.
Week 2 (visit 3):
1. The investigators will assess the subject's willingness to continue study
participation.
2. Review medication diary and medication side-effect/benefit checklist along with any
unused study medication. If the subject has not experienced any bothersome side effect
and agree to continue,he/she will be issued the next level of either the placebo or the
active medication Ketotifen (2 mg.).
3. To assure the subjects' safety, the project coordinator or a member of the research
team will complete a medication side-effect questionnaire. The subject will be asked to
schedule a weekly check-in call for week 3 and 4 and once every 2 weeks from week 4 to
week 10 (weeks 6, 8, and 10)
Week 10 (visit 4):
1. One week prior to this visit, the subject will receive a 'pain score' wrist monitor via
an express delivery service (e.g., FedEx) and will be asked to enter his/her pain level
three times a day for one week. Then return it during this visit.
2. Review medication side effect/benefit checklist, medication diary and return any unused
medication.
3. Completion of self-assessment questionnaires via computer
4. Obtain exit blood samples (approximately 17.5 ml /3.3 teaspoonfuls) from a vein in
his/her arm.
5. Undergo a thumb pressures pain sensitivity test.
|
| Criteria: |
|
Inclusion Criteria:
In order to qualify the subject:
1. must have been diagnosed with fibromyalgia by a medical doctor
2. must be between the ages of 18 to 65 years of age
3. must have a weekly overall body pain average score ≥ 4
4. must pass a screening questionnaire that calculates a physical impairment of ≥ 10
5. must be on stable doses of his/her current medication for at least past four weeks
6. must limit any changes in his/her medication(s) (e.g., dose change, addition or
discontinuation of any medication that effects the central nervous system, e.g.,
benzodiazepines, sedative/hypnotic, etc. ) during the 10-week study period unless
medically necessary
7. must report all medication including herbal supplements and over-the-counter
medications, e.g. cold medication, eye drops, etc. that he/she is currently taking to
a member of the research team
8. must be willing to maintain a medication diary provided to him/her during the 10-week
study period
9. must be willing to abstain (not take) any fibromyalgia related medication including
over-the-counter for at least 8-hours prior to each of the two testing visits
(Otherwise, he/she may take these medication(s) immediately after pain sensitivity
testing has been completed and as prescribed in-between visits)
10. must agree to use a proven method of contraception to prevent pregnancy throughout
this study
Exclusion Criteria:
The subject will not be allowed to participate if:
1. he/she has a history of seizures
2. he/she has atopic dermatitis (also called eczema) or chronic urticaria (hives)
3. he/she has chronic thrombocytopenia (a low blood platelet count)
4. she is currently pregnant, are planning to become pregnant, or is breastfeeding
5. he/she has been diagnosed by a psychiatrist with Schizophrenia or bipolar disorder
6. he/she has been diagnosed with another major rheumatic conditions (i.e. rheumatoid
arthritis, systemic lupus erythematosus, scleroderma and/or other connective tissue
diseases)
7. he/she plans to undergo an elective surgery within the study timeline
8. he/she is in the process of filing, or plan to file for disability benefits within
the study timeline
9. his/her screening labs results are abnormal (i.e., elevated SGPT and low platelet
count)
10. he/she is currently using any anti-allergy drugs (ophthalmic or oral histamine
antagonist), leukotriene inhibitors (e.g., montelukast) or prednisone
|
| NCT ID: |
|
NCT01553318 |
| Primary Contact: |
|
Principal Investigator
Dennis C. Ang, MD
Indiana University
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Indianapolis, Indiana 46202
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 22, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|